Compare BFS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | ABUS |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 848.8M |
| IPO Year | N/A | 2008 |
| Metric | BFS | ABUS |
|---|---|---|
| Price | $34.28 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $44.00 | $5.00 |
| AVG Volume (30 Days) | 41.2K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $5.67 | $239.71 |
| P/E Ratio | $30.48 | ★ $5.10 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $29.16 | $3.04 |
| 52 Week High | $35.45 | $5.10 |
| Indicator | BFS | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 50.92 |
| Support Level | $32.56 | $4.17 |
| Resistance Level | $34.99 | $4.60 |
| Average True Range (ATR) | 0.77 | 0.16 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 67.74 | 61.46 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.